Novartis has another phase 3 trial win in its quiver for targeted factor B inhibitor iptacopan, building the case for the drug as a new oral therapy for diseases caused by disorders of the complement ...

A really fast way to learn something!

Showcase your company news with guaranteed exposure both in print and online Most Admired CEOs were built for times like these. Their leadership & actions are guiding the… Discover how AI and emerging ...

Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily. Last year, despite minding other people’s business online, I didn’t know what a “trad ...